Rhumbline Advisers Cyma Bay Therapeutics, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$12.63 - $24.47 $260,998 - $505,672	20,665 Added 15.96%	150,169 $3.55 Million
Q3 2023 Nov 09, 2023	BUY	$10.86 - $17.62 $37,771 - $61,282	3,478 Added 2.76%	129,504 $1.93 Million
Q2 2023 Aug 08, 2023	BUY	$7.47 - $10.95 $941,414 - $1.38 Million	126,026 New	126,026 $1.38 Million
Q2 2022 Aug 11, 2022	SELL	$1.72 - $3.39 $174,743 - $344,407	-101,595 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$2.77 - $3.64 $11,376 - $14,949	-4,107 Reduced 3.89%	101,595 $316,000
Q4 2021 Feb 10, 2022	SELL	$3.23 - $4.6 $1,566 - $2,231	-485 Reduced 0.46%	105,702 $357,000
Q3 2021 Nov 12, 2021	BUY	$3.47 - $4.42 $7,238 - $9,220	2,086 Added 2.0%	106,187 $388,000
Q2 2021 Aug 05, 2021	SELL	$3.94 - $4.92 $48,698 - $60,811	-12,360 Reduced 10.61%	104,101 $454,000
Q1 2021 May 06, 2021	SELL	$4.23 - $6.55 $23,180 - $35,894	-5,480 Reduced 4.49%	116,461 $529,000
Q4 2020 Feb 10, 2021	BUY	$5.73 - $9.03 $83,549 - $131,666	14,581 Added 13.58%	121,941 $700,000
Q3 2020 Nov 12, 2020	SELL	$3.32 - $7.24 $47,027 - $102,554	-14,165 Reduced 11.66%	107,360 $777,000
Q2 2020 Aug 13, 2020	BUY	$1.41 - $4.25 $51,659 - $155,711	36,638 Added 43.16%	121,525 $424,000
Q4 2019 Feb 05, 2020	SELL	$1.33 - $5.93 $156 - $699	-118 Reduced 0.14%	84,887 $166,000
Q3 2019 Oct 23, 2019	SELL	$5.12 - $7.21 $2,944 - $4,145	-575 Reduced 0.67%	85,005 $435,000
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $46,808 - $105,687	7,737 Added 9.94%	85,580 $613,000
Q1 2019 May 01, 2019	SELL	$8.16 - $13.42 $840 - $1,382	-103 Reduced 0.13%	77,843 $1.03 Million
Q4 2018 Jan 31, 2019	BUY	$6.54 - $11.74 $163,872 - $294,169	25,057 Added 47.38%	77,946 $613,000
Q3 2018 Nov 07, 2018	SELL	$10.88 - $14.52 $25,807 - $34,441	-2,372 Reduced 4.29%	52,889 $586,000
Q2 2018 Aug 06, 2018	BUY	$10.66 - $14.38 $589,082 - $794,653	55,261 New	55,261 $742,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account